Cost-utility analysis of a national project to reduce hypertension in Israel
<p>Abstract</p> <p>Background</p> <p>This study aims to calculate the health effects and costs of a proposed national hypertension prevention and control program.</p> <p>Methods</p> <p>Interventions are based on experience from our two programs:...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2007-11-01
|
| Series: | Cost Effectiveness and Resource Allocation |
| Online Access: | http://www.resource-allocation.com/content/5/1/16 |
| _version_ | 1811247667649445888 |
|---|---|
| author | Dicker Dror Viskoper Reuven Ginsberg Gary Yosefy Chaim Gavish Dov |
| author_facet | Dicker Dror Viskoper Reuven Ginsberg Gary Yosefy Chaim Gavish Dov |
| author_sort | Dicker Dror |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>This study aims to calculate the health effects and costs of a proposed national hypertension prevention and control program.</p> <p>Methods</p> <p>Interventions are based on experience from our two programs: 10-year period of Ashkelon Hypertension Detection and Control Program (AHDC Program) and the Israel Blood Pressure Control (IBPC) program. The costs of a nationwide program were calculated based on economic data, training staff levels, course frequency and unit costs.</p> <p>Results</p> <p>Over the next 20 years, the program should decrease the risk in one-half of the treated hypertensive cases of the following ailments: cardiovascular events such as Acute Myocardial Infarction (AMI) and Unstable Angina Pectoris (UAP) by 16.0%, stroke by 41.2%, End stage renal disease (ESRD) by 50.0% and peripheral vascular disease (PVD) by 42.6%. In total, around 2,242 lives, 35,117 years of life or 24,433 disability adjusted life years will be saved due to decreased mortality.</p> <p>Program costs amount to $352.7 million. However savings ($537.6 million), from reduced medical treatment ($444.3 million) and reduced pharmaceutical use ($93.3 million) as a result of morbidity decreases, exceed costs by $185.0 million.</p> <p>Conclusion</p> <p>The project which saves both lives and resources should be extended nation-wide to reach as wide a population as possible.</p> |
| first_indexed | 2024-04-12T15:12:37Z |
| format | Article |
| id | doaj.art-fb23f1be3d104a30bfbcaf39704ed271 |
| institution | Directory Open Access Journal |
| issn | 1478-7547 |
| language | English |
| last_indexed | 2024-04-12T15:12:37Z |
| publishDate | 2007-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Cost Effectiveness and Resource Allocation |
| spelling | doaj.art-fb23f1be3d104a30bfbcaf39704ed2712022-12-22T03:27:42ZengBMCCost Effectiveness and Resource Allocation1478-75472007-11-01511610.1186/1478-7547-5-16Cost-utility analysis of a national project to reduce hypertension in IsraelDicker DrorViskoper ReuvenGinsberg GaryYosefy ChaimGavish Dov<p>Abstract</p> <p>Background</p> <p>This study aims to calculate the health effects and costs of a proposed national hypertension prevention and control program.</p> <p>Methods</p> <p>Interventions are based on experience from our two programs: 10-year period of Ashkelon Hypertension Detection and Control Program (AHDC Program) and the Israel Blood Pressure Control (IBPC) program. The costs of a nationwide program were calculated based on economic data, training staff levels, course frequency and unit costs.</p> <p>Results</p> <p>Over the next 20 years, the program should decrease the risk in one-half of the treated hypertensive cases of the following ailments: cardiovascular events such as Acute Myocardial Infarction (AMI) and Unstable Angina Pectoris (UAP) by 16.0%, stroke by 41.2%, End stage renal disease (ESRD) by 50.0% and peripheral vascular disease (PVD) by 42.6%. In total, around 2,242 lives, 35,117 years of life or 24,433 disability adjusted life years will be saved due to decreased mortality.</p> <p>Program costs amount to $352.7 million. However savings ($537.6 million), from reduced medical treatment ($444.3 million) and reduced pharmaceutical use ($93.3 million) as a result of morbidity decreases, exceed costs by $185.0 million.</p> <p>Conclusion</p> <p>The project which saves both lives and resources should be extended nation-wide to reach as wide a population as possible.</p>http://www.resource-allocation.com/content/5/1/16 |
| spellingShingle | Dicker Dror Viskoper Reuven Ginsberg Gary Yosefy Chaim Gavish Dov Cost-utility analysis of a national project to reduce hypertension in Israel Cost Effectiveness and Resource Allocation |
| title | Cost-utility analysis of a national project to reduce hypertension in Israel |
| title_full | Cost-utility analysis of a national project to reduce hypertension in Israel |
| title_fullStr | Cost-utility analysis of a national project to reduce hypertension in Israel |
| title_full_unstemmed | Cost-utility analysis of a national project to reduce hypertension in Israel |
| title_short | Cost-utility analysis of a national project to reduce hypertension in Israel |
| title_sort | cost utility analysis of a national project to reduce hypertension in israel |
| url | http://www.resource-allocation.com/content/5/1/16 |
| work_keys_str_mv | AT dickerdror costutilityanalysisofanationalprojecttoreducehypertensioninisrael AT viskoperreuven costutilityanalysisofanationalprojecttoreducehypertensioninisrael AT ginsberggary costutilityanalysisofanationalprojecttoreducehypertensioninisrael AT yosefychaim costutilityanalysisofanationalprojecttoreducehypertensioninisrael AT gavishdov costutilityanalysisofanationalprojecttoreducehypertensioninisrael |